sale ep ahead estim top bottom line guidanc rais
still plan seek approv dose baricitinib despit adcom
favor
ep estim consensu
ep guidanc rais prior increas
estim reflect beat revis guidanc review
sale estim drug beat
estim includ humalog strattera cymbalta alimta trulic
ciali olumi combin
forecast product forecast includ taltz due
de-stock basaglar effient cyramza jardianc tradjenta zyprexa
combin light verzenio sale line anim health
forecast sale guidanc rais
prior last publish revenu estim
gpm estim although say increas ex
fx estim sg
forecast non-oper incom net forecast tax rate
estim ad share count
line guidanc updat sg vs prior
vs prior incom net vs prior
tax rate approxim vs prior approxim
verzenio abemaciclib eu/jp approv mbc ph ii data
mbc w/herceptin taltz ph data axspa galcanezumab cgrp approv
migrain prevent ph data cluster headach lasmiditan file migrain
treatment olumi baricitinib approv ra ph ii data sle initi ph
alimta label updat nsclc cyramza full ph data high-afp
liver cancer reach met os intern data egfr nsclc relay
jardianc initi ph ckd ph data glucagon nasal file hypoglycemia
tanezumab w/pfe ph data oa pain intern tradjenta ph data cv outcom
studi carmelina carolina intern readout trulic cv outcom intern ph
data rewind ultra-rapid insulin ph intern data mirikizumab ph
data psoriasi uc elanco decis statu post strateg review
pleas see page report import disclosur
number promis new drug rollout late-stag agent pois launch
next year give us confid top-tier sale ep growth prospect pipelin
visibl improv overal margin target appear achiev estim
ep compound-annual-growth-rate among best pharma dividend yield attract
perform diabet busi
galcanezumab approv migrain
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
alimta declin rapidli
margin expans plan delay
margin expans sooner greater
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas
oncolog among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
